Welcome to our dedicated page for Exagen news (Ticker: XGN), a resource for investors and traders seeking the latest updates and insights on Exagen stock.
Exagen Inc. (Nasdaq: XGN) is a commercial-stage diagnostics company that describes itself as a leading provider of autoimmune diagnostics and autoimmune testing solutions. Based in San Diego County, California, Exagen focuses on chronic and debilitating autoimmune conditions, particularly autoimmune rheumatic diseases. Its news flow reflects both its operational performance and its scientific and clinical activities in this specialized area.
Company news frequently covers financial results and operational updates, including quarterly earnings releases, preliminary annual results, and related guidance. These updates often discuss revenue trends, test volume for the AVISE CTD panel, average selling price metrics, and cash and cash equivalents, giving investors insight into Exagen’s commercial progress as an autoimmune diagnostics provider.
Exagen’s news also highlights developments in its testing portfolio and research programs. The company reports on enhancements to AVISE CTD, such as the commercial launch of seronegative rheumatoid arthritis markers for anti-PAD4, and on scientific milestones like the acceptance of multiple abstracts at the American College of Rheumatology’s annual meeting. These abstracts address topics including urinary biomarker panels for lupus nephritis, kidney-specific biomarker panels, T cell biomarkers, and multianalyte lupus risk scores.
Additional announcements include participation in healthcare and diagnostics investor conferences and leadership appointments, such as the addition of a Chief Scientific Officer and new board members with experience in life sciences and medical technology. Together, these news items give a view into Exagen’s financial performance, scientific focus, and corporate development. Investors and observers can use the XGN news page to follow how the company reports on its autoimmune testing business, research activities, and strategic initiatives over time.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Exagen Inc. (Nasdaq: XGN) plans to release its financial results for Q1 2023 on May 15, 2023, after market close. The conference call to discuss these results will be hosted by CEO John Aballi and CFO Kamal Adawi at 4:30 PM ET. Analysts and investors can join the call by dialing the provided numbers or accessing it via the Exagen investor relations website. A replay will be available until May 29, 2023. Exagen specializes in autoimmune diagnostic solutions and aims to enhance precision medicine through its AVISE® testing products.
Exagen Inc. (Nasdaq: XGN) announced fourth quarter and full year 2022 financial results, achieving a record 135,210 AVISE® CTD tests. Total revenue for 2022 was $45.6 million, down from $48.3 million in 2021. The fourth quarter saw revenues of $12.8 million, slightly up from $12.7 million year-over-year. However, gross margin dropped to 50.9% from 61.1% due to increased costs. Operating expenses rose to $27.3 million, influenced by a one-time goodwill impairment and severance charges. The net loss for 2022 was $47.4 million, compared to a loss of $26.9 million in 2021. The company raised its revenue guidance for the first quarter of 2023 to $9.2-$9.7 million.
Exagen Inc. (Nasdaq: XGN) will announce its financial results for the fourth quarter and full year ended December 31, 2022, on March 20, 2023, after market close. CEO John Aballi and CFO Kamal Adawi will discuss these results in a conference call at 4:30 PM ET. Interested listeners can dial (201) 389-0918 for U.S. participants or (877) 407-0890 for international attendees. A replay will be available until April 3, 2023. Exagen specializes in autoimmune diagnostic testing solutions, focusing on precision medicine to assist patients and healthcare providers.
Exagen Inc. (Nasdaq: XGN), a leader in autoimmune testing solutions, announced its participation in two investor conferences in March 2023. The first is the Cowen 43rd Annual Health Care Conference from March 6-8, where CEO John Aballi and CFO Kamal Adawi will engage in a fireside chat on March 6 at 10:30 AM ET. The second is a virtual participation in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum on March 21-22, with a separate chat on March 22 at 1:30 PM ET. Interested parties can access the live webcasts through Exagen’s website.